Chongqing Lummy Pharmaceutical Co., Ltd.

SZSE:300006 Stock Report

Market Cap: CN¥3.7b

Chongqing Lummy Pharmaceutical Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Rongzhao Qiu

Chief executive officer

CN¥830.8k

Total compensation

CEO salary percentagen/a
CEO tenure4.6yrs
CEO ownershipn/a
Management average tenure5.7yrs
Board average tenure4.6yrs

Recent management updates

Recent updates

Health Check: How Prudently Does Chongqing Lummy Pharmaceutical (SZSE:300006) Use Debt?

Dec 30
Health Check: How Prudently Does Chongqing Lummy Pharmaceutical (SZSE:300006) Use Debt?

Some Confidence Is Lacking In Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006) As Shares Slide 26%

Dec 30
Some Confidence Is Lacking In Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006) As Shares Slide 26%

Subdued Growth No Barrier To Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006) With Shares Advancing 32%

Nov 15
Subdued Growth No Barrier To Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006) With Shares Advancing 32%

We Think Chongqing Lummy Pharmaceutical's (SZSE:300006) Healthy Earnings Might Be Conservative

Oct 29
We Think Chongqing Lummy Pharmaceutical's (SZSE:300006) Healthy Earnings Might Be Conservative

Revenues Not Telling The Story For Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006) After Shares Rise 36%

Oct 01
Revenues Not Telling The Story For Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006) After Shares Rise 36%

What Chongqing Lummy Pharmaceutical Co., Ltd.'s (SZSE:300006) 36% Share Price Gain Is Not Telling You

Oct 01
What Chongqing Lummy Pharmaceutical Co., Ltd.'s (SZSE:300006) 36% Share Price Gain Is Not Telling You

Risks To Shareholder Returns Are Elevated At These Prices For Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006)

Feb 27
Risks To Shareholder Returns Are Elevated At These Prices For Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006)

CEO

Rongzhao Qiu (30 yo)

4.6yrs

Tenure

CN¥830,800

Compensation

Mr. Rongzhao Qiu is General Manager of Chongqing Lummy Pharmaceutical Co., Ltd. from June 12, 2020.

Leadership Team

NamePositionTenureCompensationOwnership
Rongzhao Qiu
General Manager4.6yrsCN¥830.80kno data
Xue Feng Leng
Deputy General Manager and Vice Chairman8.8yrsCN¥867.50kno data
Wen Lai
Financial Director8.8yrsCN¥678.40kno data
Song Lin
Deputy GM & Director2.1yrsCN¥410.20kno data
Dan Cui
Deputy GM6.8yrsCN¥359.70k0.0016%
CN¥ 59.5k

5.7yrs

Average Tenure

50yo

Average Age

Experienced Management: 300006's management team is seasoned and experienced (5.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Xue Feng Leng
Deputy General Manager and Vice Chairman8.8yrsCN¥867.50kno data
Song Lin
Deputy GM & Director2yrsCN¥410.20kno data
Yuan Yuan
Chairman of Supervisory Board7.9yrsno datano data
Xujiang Chen
Independent Director4.6yrsCN¥88.50kno data
Geng Chen
Independent Director4.6yrsCN¥88.50kno data
Jiansheng Liang
Chairman3.1yrsCN¥729.40kno data
Rihua Ou
Director4.6yrsno datano data
Weiyan Tang
Director4.6yrsno datano data
Changbi Li
Independent Director4.6yrsCN¥88.50kno data
Huichuan Xu
Employee Supervisor11yrsno datano data
Mingyue Tan
Supervisor3.1yrsno datano data
Hai Run Wang
Director2yrsno datano data

4.6yrs

Average Tenure

47yo

Average Age

Experienced Board: 300006's board of directors are considered experienced (4.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/28 23:27
End of Day Share Price 2025/01/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Chongqing Lummy Pharmaceutical Co., Ltd. is covered by 11 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullChangjiang Securities Co. LTD.
Chao LiCitic Securities Co., Ltd.
Wen Liang CuiFounder Securities Co., Ltd.